Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8041 to 8055 of 8901 results

  1. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

    Withdrawn advice

  2. Danis stent for acute oesophageal variceal bleeds (MIB185)

    This advice has been updated and replaced by NICE healthtech guidance 574.

    Withdrawn advice

  3. Endo-SPONGE for colorectal anastomotic leakage (MIB188)

    This advice has been updated and replaced by NICE healthtech guidance 605.

    Withdrawn advice

  4. The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

    This advice has been updated and replaced by NICE healthtech guidance 566.

    Withdrawn advice

  5. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)

    This advice has been updated and replaced by NICE healthtech guidance 611.

    Withdrawn advice

  6. myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)

    This advice has been updated and replaced by NICE medical technologies guidance 68.

    Withdrawn advice

  7. Space from Depression for treating adults with depression (MIB215)

    This advice has been updated and replaced by NICE HealthTech guidance 675.

    Withdrawn advice

  8. FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)

    This advice has been updated and replaced by NICE healthtech guidance 682.

    Withdrawn advice

  9. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  10. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  11. Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)

    In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008

    Withdrawn guidance

  12. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Withdrawn guidance

  13. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  14. Alteplase for the treatment of acute ischaemic stroke (TA122)

    This guidance has been updated and replaced by NICE technology appraisal guidance 264 issued in September 2012.

    Withdrawn guidance

  15. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance